ArticleAmerican heart journal2019
Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design.
Article in American heart journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 5 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Influenza Vaccination for Cardiovascular Prevention: Further Insights from the IAMI Trial and an Updated Meta-analysis.Current cardiology reports · 2022Pooled it
- Association of Influenza Vaccination With Cardiovascular Risk: A Meta-analysis.JAMA network open · 2022Pooled it
- Moving the Needle on Atherosclerotic Cardiovascular Disease and Heart Failure with Influenza Vaccination.Current atherosclerosis reports · 2021Pooled it
- Effects of Influenza Vaccine on Mortality and Cardiovascular Outcomes in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis.Journal of the American Heart Association · 2021Pooled it
- Protective effect of influenza vaccination on cardiovascular diseases: a systematic review and meta-analysis.Scientific reports · 2020Pooled it
- Influenza vaccination reduces incidence of peripheral arterial occlusive disease in elderly patients with chronic kidney disease.Scientific reports · 2021Trial
- Trial
- Large-Scale Disease-Wide Association Study Identified Predisposition Links Between Influenza and Cardiovascular Diseases.Cardiovascular toxicology · 2026Article
- Chronic Diseases and Influenza Vaccines.Vaccines · 2025Review
- Impact of infection-related admission in patients with heart failure: a 10 years national cohort study.Scientific reports · 2023Article
- Primary prevention of acute cardiovascular events by influenza vaccination: an observational study.European heart journal · 2023Observational
- Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions.Cardiovascular research · 2023Review
- Vaccines and cardiovascular outcomes: lessons learned from influenza epidemics.European heart journal supplements : journal of the European Society of Cardiology · 2023Article
- The impact of influenza vaccination on cardiovascular diseases.European heart journal supplements : journal of the European Society of Cardiology · 2023Article
- What if flu vaccination is the most responsible thing to do for cardiovascular health in the upcoming season?European heart journal supplements : journal of the European Society of Cardiology · 2023Article
- Risk of arterial and venous thromboses after COVID-19.The Lancet. Infectious diseases · 2022Article
- Article
- Vaccination for Respiratory Infections in Patients with Heart Failure.Journal of clinical medicine · 2021Review
- A Review of Vaccinations in Adult Patients with Secondary Immunodeficiency.Infectious diseases and therapy · 2021Review
- Lockdown Britain: Evidence for reduced incidence and severity of some non-COVID acute medical illnesses.Clinical medicine (London, England) · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors at 12 institutions in 11 countries.
Funding
Abstract
backgroundInfluenza is associated with an increase in the risk of cardiac and other vascular events. Observational data and small randomized trials suggest that influenza vaccination may reduce such adverse vascular events. RESEARCH DESIGN AND
methodsIn a randomized controlled trial patients with heart failure are randomized to receive either inactivated influenza vaccine or placebo annually for 3 years. Patients aged ≥18 years with a clinical diagnosis of heart failure and NYHA functional class II, III and IV are eligible. Five thousand patients from 10 countries where influenza vaccination is not common (Asia, the Middle East, and Africa) have been enrolled. The primary outcome is a composite of the following: cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and hospitalizations for heart failure using standardized criteria. Analyses will be based on comparing event rates between influenza vaccine and control groups and will include time to event, rate comparisons using Poisson methods, and logistic regression. The analysis will be conducted by intention to treat i.e. patients will be analyzed in the group in which they were assigned. Multivariable secondary analyses to assess whether variables such as age, sex, seasonality modify the benefits of vaccination are also planned for the primary outcome.
conclusionThis is the largest randomized trial to test if influenza vaccine compared to control reduces adverse vascular events in high risk individuals. TRIAL REGISTRATION NUMBER: Clinicaltrials.govNCT02762851.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.